Quarterly revenue reached ~$1.53m, with FY26 revenue up ~210% year-over-year, driven by clinic expansion and strong patient demand. Early clinical results showed significant improvement in depression symptoms, and regulatory changes plus global partnerships are expected to accelerate growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.